Results 241 to 250 of about 192,321 (310)

Aptamers in cancer therapy: Why has clinical translation lagged behind preclinical promise? [PDF]

Biomed Pharmacother
Tran TT, Tran VL, Fishel ML, Nguyen BT, Zhang J, Condello S, Zhong X, Schmidt M.   +7 more
europepmc   +1 more source

Preclinical evaluation of AHR-1118, a potential antidepressant drug.

Current therapeutic research, clinical and experimental, 1970
D N, Johnson, W H, Funderburk, J W, Ward
openaire   +1 more source

Advancing target discovery through disease-specific integration of multi-modal target identification models and comprehensive benchmarking system. [PDF]

Sci Rep
Leung H, Duan C, Gou W, Chen J, Xin Y, Zheng Z, Naumov V, Gennert D, Zhang M, Aliper A, Ren F, Izumchenko E, Pun FW, Zhavoronkov A.   +13 more
europepmc   +1 more source

When Selectivity Increases Uncertainty: Context-Dependent Pharmacology in Antibody Drug Development. [PDF]

Clin Transl Sci
Liao X, Cao Y.
europepmc   +1 more source

New approach methodologies for drug discovery. [PDF]

Cell
Liu W, Pang PD, Wu CA, Tagle D, Wu JC.
europepmc   +1 more source

BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. [PDF]

Pharmaceutics
Mateescu DM, Gavrilescu DM, Constantinescu FE, Oancea C, Ilie AC, Folescu R, Popa MD, Iurciuc S, Muresan CO, Enache A.   +9 more
europepmc   +1 more source

Toxicity assessment in preclinical histopathology via class-aware Mahalanobis distance for known and novel anomalies. [PDF]

Sci Rep
Graf O, Patel D, Groß P, Lempp C, Hein M, Heinemann F.   +5 more
europepmc   +1 more source